|
|
Article: InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting.(Report)
- Article from:
- Clinical Trials Week
- Article date:
- October 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
InteKrin Therapeutics Inc. announced positive results for INT131 in a 24 week Phase 2b study at the 45th European Association for the Study of Diabetes Meeting in Vienna, Austria. An overview of the data will be presented at 1:45 PM Friday, October 2, 2009 by InteKrin Therapeutics' Chief Medical Officer, Alex DePaoli, MD. His presentation is entitled "Impact of INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), on Glycemic Control in Patients with Type 2 Diabetes in a 24-Week Phase 2b Study (INT131-007)." In this study INT131 demonstrated a superior side effect profile with comparable efficacy when tested side-by-side against 45 mgs daily pioglitazone (Actos=AE) ...
Related newspaper, magazine, and journal articles:
|
|
Article: InteKrin Therapeutics to Present at the 27th Annual ...
PR Newswire;
January 8, 2009 ;
700+ words
... ... Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th ... in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear ... www.intekrin.com)/ InteKrin Therapeutics is a privately-held clinical ...
|
|